Real-World data shows promise for targeted lung cancer drug
NCT ID NCT06678555
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study reviews medical records of 35 adults with a specific lung cancer (ROS1-positive NSCLC) that had not been controlled by other treatments. All participants took lorlatinib pills at home until their cancer stopped responding. Researchers will analyze how long the drug kept the cancer from growing and how safe it was in everyday use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
22 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a retrospective, observational study to investigate effectiveness, treatment patterns, and gene mutation profile of ROS1-positive NSCLC patients who had received lorlatinib after any TKI treatment failure in Taiwan using an EMR database, NTUH-iMD. Study population consists of patients who were diagnosed with ROS1-positive NSCLC and received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023 after any TKI treatment failure.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients are aged 18 years or older on index date 2. Patients have confirmed diagnosis of ROS1-positive NSCLC 3. Patients have received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023 Exclusion Criteria: 1\. Patients participated in any clinical trials using lorlatinib during the observation period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut microbes may hold key to why cancer immunotherapy works for some
- Why lung cancer patients lose weight: scientists measure the Body's fuel switch
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Can a targeted pill be safely used for RET-Driven cancers in india?
- New drug combo takes aim at a Hard-to-Treat lung cancer mutation
- Can an Antibody-Drug conjugate crack resistant EGFR lung cancer?